HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
申请人:AMGEN INC.
公开号:US20170320860A1
公开(公告)日:2017-11-09
Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures:
where the definitions of the variables are provided herein.
[EN] CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE À SUBSTITUTION CYCLOALKYLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
申请人:AMGEN INC
公开号:WO2018093577A1
公开(公告)日:2018-05-24
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures:(I) (II) where the definitions of the variables are provided herein.
[EN] ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE SUBSTITUÉS PAR ALKYLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
申请人:AMGEN INC
公开号:WO2018093576A1
公开(公告)日:2018-05-24
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
The present invention provides heterocyclylamine derivatives of Formula I:
wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
[EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE PIM
申请人:ARRAY BIOPHARMA INC
公开号:WO2012154274A1
公开(公告)日:2012-11-15
Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.